TP53 and breast cancer: For example, Dumay et al. studied the mutational spectrum of TP53 in 572 breast cancers and found that luminal breast cancers were predominantly missense mutations, particularly A:T to G:C transitions, whereas basal breast cancers showed a higher incidence of truncating mutations [40].